Cancer treatment is often complicated by resistance to conventional anti-cancer treatment and to more recently developed immunotherapy and gene therapy. These therapeutic modalities aim at activating death pathways within cancer cells. Attempts to activate the apoptotic death pathway, by overexpressing proapoptotic signals, are compromised by cancer defense mechanisms, which disrupt the apoptotic-signaling cascade downstream of the overexpressed component. Here, we describe a therapeutic option of triggering apoptosis without activating the apoptotic-signaling cascade or using the native apoptosis executioner nuclease. We have engineered Deoxyribonuclease-1 (DNase1), a waste-management enzyme, by deleting its signal peptide, adding a nuclear localization signal, and mutating its actin-binding site. Apoptosis studies and colony-forming assay for assessing cell viability were conducted in apoptosis-resistant Mel-Juso human melanoma cells. The modified DNase1 reduced cell viability by 77% relative to controls. It also induced typical microscopic features of cellular apoptosis, such as Terminal Transferase dUTP Nick-End Labelingpositive cells and DNA fragmentation. Quantification of apoptosis by Laser scanning cytometry demonstrated high-killing efficiency of 70-100%. The results suggest that this modified DNase1 can efficiently eliminate apoptosis-resistant cancer cells through apoptosis. Coupled to different tissue-specific gene expression elements, this recombinant DNase1 may serve as a platform for eliminating a variety of cancer types.
Introduction
Cancer treatment is often complicated by resistance to currently available therapeutic modalities, such as radiotherapy, chemotherapy and the more recently developed immunotherapy and gene therapy. These treatments use a variety of strategies to activate death pathways within cancer cells. However, 'defense mechanisms' of cancer cells can induce resistance by deactivating various components within their death pathways. Thus, searching for a new efficient therapeutic intervention is warranted.
Extrinsic apoptotic pathways start with a cascade of signals that extend from the upstream death receptors (for example, Fas/CD95 and TNFa) on the cell surface to the downstream endonucleases within the nucleus. Activated endonucleases, in turn, induce intranucleosomal DNA fragmentation. At the final stage, cellular debris is cleared by phagocytes. Typically, the entire process neither damages neighboring cells nor provokes an immune reaction.
Inducing apoptosis, by intervening along the apoptoticsignaling cascade, has been a major approach in cancer gene therapy. However, malignant cells can show resistance to this mechanism by disrupting various components along the cascade. This results in prevention of protein synthesis, deactivation of mutations, or overexpression of inhibitors, leading to deficiency of active components, such as Fas/CD95, [1] [2] [3] caspase-8 or caspase-10. 3, 4 Cascade disruption can also result from upregulation of anti-apoptotic signals such as XIAP, cIAP1 or cIAP2, which bind and inhibit caspases-3, -7 and -9. [5] [6] [7] One way of circumventing all possible types of upstream signaling disruptions is by triggering the apoptosis mechanism at the bottom of the cascade, namely, by overexpressing executioner endonucleases.
Apoptotic endonucleases include 'cell-autonomous nucleases' and 'waste-management nucleases'. 8 Autonomous nucleases, such as CAD and DNase-g, have access to the intact nucleus and cleave nuclear DNA as the cell undergoes apoptosis. By contrast, waste-management nucleases, such as Deoxyribonuclease-1 (DNase1) and DNase II, do not have access to the intact nucleus and are mainly involved in digestion of DNA fragments derived from other cells that undergo necrosis or late-stage apoptosis.
The waste-management endonuclease, DNase1, is a B30 kDa glycoprotein that cleaves both singleand double-stranded DNA through hydrolysis of the phosphodiester bond, yielding 5 0 -phosphorylated and 3 0 -hydroxylated oligonucleotides. Two features deny DNase1 access to the nucleus. The first is the presence of a signal peptide (SP), which directs secretion of DNase1 protein out of the cell, or confines it to intracellular endosomes, Golgi apparatus or nuclear envelope. 9 The second is the absence of a nuclear localization signal (NLS) that transports proteins across the nuclear envelope. 8 DNase1 may serve well the purpose of triggering apoptosis. First, DNase1 is a highly potent DNA-degrading enzyme. It is expected to be highly cytotoxic in mammalian cells as it can effectively digest both single-and double-stranded DNA, although it digests double-stranded DNA more than 100 times faster than single-stranded DNA. [10] [11] [12] Thus, a small amount can induce cell death. 13 Second, as a waste-management enzyme, DNase1 has no access to the nucleus under normal physiological conditions, thus, it is conceivable that DNase1 would encounter fewer nuclear inhibitors than cell-autonomous nucleases. Third, DNase1 has only one known major natural inhibitor, actin, which is present in high concentrations both in the cytoplasm and nucleus. [14] [15] [16] G-actin, a monomeric form of actin, inhibits DNase1 by forming a stoichiometric (1:1) complex. Finally, DNase1 is physiologically a benign extracellular enzyme present ubiquitously in blood serum and body secretions. [17] [18] [19] [20] Also, it has been safely used as a therapeutic spray in cystic fibrosis patients to degrade DNA and reduce sputum viscosity. 21 To engineer DNase1 protein that could degrade nuclear DNA, we addressed four obstacles: (i) nuclear envelope, which serves as a physical barrier; (ii) absence of NLS, which provides access to the nucleus; (iii) SP, which directs DNase1 away from the nucleus (to be secreted or compartmentalized); and (iv) actin, a major DNase1 inhibitor.
In this study, we pursue an anti-cancer therapeutic approach of triggering apoptosis without activating the apoptotic-signaling cascade. We have bypassed the cascade and replaced the cell-autonomous nuclease with an engineered waste-management enzyme. The engineered gene constructs encode a DNase1 protein that lacks an SP, is fused with an NLS, and is modified at the actinbinding site. We show that these constructs demonstrate high-killing efficiency through apoptosis in human melanoma cells.
Materials and methods

Materials
Dulbecco's phosphate-buffered saline, RPMI-1640 medium, fetal calf serum, L-glutamine (200 mmol) and 0.5% Trypsin/5.3 mmol EDTA were purchased from Fisher (Fairlawn, NJ) and Invitrogen (Grand Island, NY). Dimethyl sulfoxide was purchased from Sigma (St Louis, MO).
Cell culture and transfection
The human melanoma Mel-Juso cell line (DSMZ, Braunschweig, Germany) was cultured in RPMI-1640 medium. The medium was supplemented with 10% fetal calf serum and 1% L-glutamine. The cells were grown to confluence and re-seeded for at least 24 h before transfection. Cultures were maintained at 37 1C in a humidified 5% CO 2 atmosphere. Cells were plated in six-well plates at a density of 8 Â 10 5 cells per well for both Terminal Transferase dUTP Nick-End Labeling (TUNEL) and DNA fragmentation assays; at a density of 4 Â 10 5 cells per well for western blotting, and at a density of 600 cells per well for the colony forming assay. After 24 h, cells were transfected in a final volume of 1 ml with 2 mg of DNA (gene construct) using Lipofectamine LTX and Plus reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. After 4 h, fresh medium was added and cells were incubated until set times for harvesting were reached. For laser scanning cytometry (LSC), cells were grown on 8-chamber slides (Lab-Tek II: Nalgene, Nunc International, Naperville, IL) and transfected with 0.5 mg of each DNase1 construct using Lipofectamine LTX and Plus reagent as described above.
Constructs
The generated DNase1 constructs and primers are described in Figure 1 and Table 1 , respectively. The SP was removed by deleting the 22 amino acids upstream of the first DNase1 codon. We rendered partial resistance to actin by mutating one of several amino acids involved in binding actin, A114F, in DNase1 constructs C11, C13, C18 and C19. We also compromised the catalytic activity of the enzyme by mutating one of the two main catalytic sites, H252A, in DNase1 constructs C18 and C19. We added the SV40 nuclear localization signal (NLS), PPKKKRKV, 22 to the DNase1 gene at the N-terminus of gene-constructs C07, C13 and C19, and at the C-terminus of gene-constructs C09, C11 and C18.
The wild-type DNase-1 open reading frame (Accession No. NM_005223) was obtained from the GATEWAY donor vector pDONR223 (Open BioSystems, Huntsville, AL) and subcloned in frame into a green fluorescence protein (GFP)-tagged eukaryotic expression vector, GATEWAY pcDNA-DEST47 (Invitrogen), driven by a cytomegalovirus promoter, using the manufacturer's instructions, generating construct C14. All subsequent deletions, insertions and site-directed mutations were generated using QuikChange Lightning Site-Directed Mutagenesis Kit (no.210518; Stratagene, Cedar Creek, TX) following the manufacturer's instructions. To create very long and stable primer pairs to be used in the mutagenesis reactions, the Klenow fragment of DNA polymerase was used to elongate oligonucleotides (Integrated DNA Technologies, Coralville, IA) from an overlapping region where the pairs were annealed. 23 DNA was extracted from bacterial clones using maxiprep/ miniprep kits (K2100-16; Invitrogen/ 27405; Qiagen, Germantown, MD) as per manufacturers' instructions and sent for sequencing (Applied Genomics Technology Center (AGTC), Detroit, MI). The chloramphenicol acetyl transferase (CAT) reporter plasmid (pcDNA/ GW-47/CAT) served as a control for assessing possible non-specific effects of overexpressed non-DNase1 protein on apoptosis and for measuring transfection efficiency of TUNEL-positive cells as measured by LSC (no.12281-010, Invitrogen).
GFP was deleted from C14 using P3-for-20p6 and P6-rc primers to generate wild-type DNase-1 (C03). SV40-NLS was inserted at the N-terminus and C-terminus of C14 to generate constructs C01 and C04, respectively. C01 was generated with P1-NLS-for and P2-NLS-rc primers, and C04 was generated with P3-NLS-for and P4-NLS-rc primers. The SP was removed from C04 to generate C08 using P5-for and P2-20p5-rc primers, and removed from C01 to generate C06 using P5-for and P2-NLS-20p5-rc primers. GFP was removed from C08 using P3-NLS-for and P6-NLS-rc primers to generate C09. GFP was also removed from C06 using P3-for-20p6 and P6-rc primers to generate C07. Alanine was mutated to phenylalanine at position 114 of DNase1 in C09 and C07 constructs using 114 and 114-rc primers to generate C11 and C13, respectively. To knockdown the enzymatic activity of DNase-1, histidine was mutated to alanine at position 252 of DNase1 in C11 and C13 constructs using ForPrimer252HtoA and RevPrimer252HtoA primers to generate C18 and C19, respectively. Sequencing confirmed the nucleotide composition of the generated DNase1 gene constructs (AGTC). ÀDDCT method. 24 Experiments were performed three times.
Western blot for protein expression
Cell lysates were collected 12, 24 and 36 h after transfection with various DNase1 constructs in 250 ml of 1 Â NuPAGE LDS sample buffer (Invitrogen), passed 10 times through a 20-gauge needle and stored at À20 1C until blotting. Electrophoresis of protein lysates (50 ml) was conducted through NuPAGE 4-12% Bis-Tris gels (Invitrogen) and blotted onto a PVDF membrane (FluorTrans, Ann Arbor, MI). Membranes were probed with primary anti-DNase1 (SC30058; Santa Cruz, CA) and anti-Beta-Actin (a5316, Sigma, St. Louis, MO) antibodies, followed by secondary antibodies conjugated to Alexa Fluor 680 (Invitrogen, Eugene, OR) or IR Dye 800 (Rockland, Gilbertsville, PA). Bound antibodies were detected at 700 or 800 nm, as indicated, using the Odyssey system (Li-Cor Biosciences, Lincoln, NE).
In vitro DNase1 activity assay
The proteins of the different DNase1 constructs were synthesized using equal amounts (250 ng) of each construct's plasmid DNA as a template in an in vitro transcription-translation kit (PureExpress, New England Biolabs, Ipswich, MA) according to the manufacturer's instructions. As previously demonstrated, 25, 26 DNase1 activity was determined quantitatively by ELISA (enzyme-linked immunosorbent assay; Orgentec Diagnostika GmbH, Mainz, Germany) according to the manufacturer's instructions. In short, samples were added to a DNA-coated 96-well microplate and incubated for 1 h at 37 1C. Horseradish peroxidase-conjugated anti-DNase1 antibodies were added and incubated for 15 min at room temperature to react with the remaining uncleaved DNA. The intensity of the color developed during the enzymatic reaction (hydrolysis of horseradish peroxidase-substrate, 3,3 0 ,5,5 0 -tetramethyl-benzidine and acid addition) was measured at OD450 using the SPECTRAmax GEMINI XS microplate spectrofluorometer (Molecular Devices, Sunnyvale, CA). Color intensity in the ELISA assay reflects the amount of intact DNA substrate remaining after exposure to DNase1. As the catalytic activity of a DNase1 gene construct increases, less DNA substrate remains intact and the colorimetric level is lower. A standard series, as well as positive and negative controls were included in the kit.
Colony forming assay for cell viability Cells were plated in six-well plates at a density of 600 cells perwell. After 24 h, the cells were transfected with various DNase1 constructs or controls as described above and were allowed to grow for 12-14 days. The cells were then fixed with absolute ethanol for 30 min, stained with 1% crystal violet in distilled water and counted (one colony X30 cells). The cells were plated in triplicates and the experiments were repeated five times.
Morphological assessment of apoptosis
Characteristic changes in cell morphology used to detect apoptosis included cell membrane blebbing, cytoplasm and nuclear condensation, and apoptotic bodies. Morphological changes were visualized by phase contrast and fluorescence microscopy using the Olympus IX71 Inverted Microscope (Olympus, Centervalley, PA) and SlideBook 4.2 software (Olympus, Denver, CO).
TUNEL assay for apoptosis
At 24 h after cells were transfected with various DNase1 constructs or controls as described above, the cells were treated directly in the wells with DeadEnd Fluorometric TUNEL System (Promega, Madison, WI) according to the manufacturer's instructions. After fixation with 4% formaldehyde, cell nuclei were counterstained with Hoechst 33258 (Invitrogen, Eugene, OR) and visualized with the IX71 Inverted Microscope (Olympus) and SlideBook 4.2 software (Olympus).
LSC for apoptosis
At 24 h after cells were transfected with various DNase1 constructs or controls as described above, the cells were treated with the DeadEnd Fluorometric TUNEL System (Promega) according to the manufacturer's instructions for detection of apoptotic cells. Cells were counterstained with propidium iodide as previously described. 27 Fluorescein-TUNEL-positive cells were scanned using the Â 20 objective and were quantified by LSC (CompuCyte, Cambridge, MA). Cells were excited by an argon laser at 488 nm, and emitted fluorescence was collected through a 530±30 nm band pass filter (green-FITC/TUNEL) and a 625 ± 28 nm band-pass filter (red-propidium iodide). Cell population data were analyzed by WinCyte 3.7 (CompuCyte). Cells were plated in triplicate and at least 2000 cells were measured per sample.
DNA fragmentation assay for apoptosis
At 24 h after cells were transfected with various DNase1 constructs or controls as described above, cells were collected and lysed. Genomic DNA was purified using an Apoptotic DNA Ladder Kit (Roche, Mannheim, Germany) according to the manufacturer's instructions.
After 20 min of treatment with RNase A (200 mg ml À1 ; Invitrogen), the samples were analyzed on a 1% agarose gel supplemented with Syto60 DNA binding dye (Invitrogen, Eugene, OR) and visualized with the Odyssey system (Li-Cor Biosciences, Lincoln, NE).
Statistics
Data were evaluated graphically and analytically to determine whether a transformation was required to meet the assumptions of the normal theory tests. Colony count, LSC and QRT-PCR data required a log transformation, whereas color intensity in the ELISA assay for DNase1 activity did not. Linear models with robust standard errors were fitted with indicator variables for each of the constructs and for experiments when appropriate. Posthoc tests were used to compare constructs with adjustment for multiple comparisons made using Holm's procedure.
Results
DNase1 gene construct compositions and catalytic activity DNase1 gene construct compositions. DNase1 gene constructs were generated by fusing an NLS to either the N-terminus or C-terminus of the DNase1 gene, and by fusing GFP to the C-terminus directly to or downstream of the fused NLS. In addition, mutations were introduced into the DNase1 gene composition to knockdown DNase1 protein binding to actin (C13 with NLS at the N-terminus; C11 with NLS at the C-terminus), and both actin and catalytic activity (C19 with NLS at the N-terminus; C18 with NLS at the C-terminus). The resulting DNase1 gene constructs are presented in Figure 1 .
In vitro DNase activity assay. We confirmed by an in vitro DNase activity assay that all DNase1 construct proteins displayed catalytic activity (Figure 2) . Also, we assessed whether knocking down the activity site of DNase1 by a histidine to alanine substitution at position 252 resulted in decreased DNA-degradation activity. The ELISA assay suggests that the H252A mutation in actin-resistant DNase1 gene constructs, C11 and C13, decreased their ability to degrade DNA (C11 vs C18, P ¼ 0.0005; C13 vs C19, P ¼ 0.001; Figure 2) . No difference in DNA degradation activity was observed between C11 and C13 (P ¼ 0.24).
All DNase1 gene constructs were transcribed into mRNA and translated into protein in Mel-Juso human melanoma cells Quantification of DNase1 gene construct expression by QRT-PCR for RNA expression. We validated by QRT-PCR that all tested DNase1 gene constructs were transcribed into mRNA at all tested time points; 12, 24 and 36 h post-transfection (Figure 3a) . With the exception of C13, which at the 24 h time point had a transcription level below that of C07 and C19 (Po0.001), transcription levels did not vary significantly between DNase1 gene C19  C13  C07  C18  C11  C09  WT  Mock  Cat-G  C19  C13  C07  C18  C11  C09  WT  Mock  Cat-G  C19  C13  C07  C18  C11  C09  WT  Mock Cat-G Modified DNase1 triggers apoptosis in melanoma K Rosner et al constructs at 12 h, 24 h and 36 h post-transfection. The decreased transcription level of C13 relative to C07 and C19 at 24 h post-transfection was not reflected in the protein expression level or in the cell viability and apoptosis levels described below.
Western blot analysis for protein expression. We validated by western blotting that all DNase1 gene constructs tested were translated into protein at 12 h, 24 h and 36 h post-transfection (Figure 3b ). The synthesis of proteins with an NLS fused to the N-terminus (C07, C13 and C19) was considerably lower than the synthesis of proteins with an NLS fused to the C-terminus (C09, C11 and C18) (Figure 3b ). Previously, low DNase1 protein synthesis was attributed to elimination of the N-terminal SP. 28 This contradicts our finding of high synthesis levels of C09, C11 and C18 (Figure 3b ) despite lacking an N-terminal SP. It is plausible that structural changes at the N-terminus, such as NLS fusion, decreased the efficiency of protein synthesis. Another difference between the N-terminal and C-terminal NLS-fused proteins was the detection of one band and two bands, respectively (Figure 3b ). The shift in band migration and the presence of two bands for DNase1 were attributed to the extent of glycosylation at two potential N-glycosylation sites, at amino acids 18 and 106. [29] [30] [31] This suggests that the NLS fused to the N-terminus structurally interferes with the extent of glycosylation, resulting in only one isoform as compared with two isoforms for proteins fused with an NLS at the C-terminus (Figure 3b ). 31 Localization of recombinant DNase1 protein after substitution of the SP with an NLS in melanoma cells Fluorescence microscopy assessment. We analyzed the localization of NLS-fused DNase1 proteins in Mel-Juso cells 24 h after transfection, before and following SP elimination (Figure 4) . Fusion of an NLS to either the N-terminus or C-terminus of SP-DNase1 did not change the cytoplasmic distribution, as is characteristic for a secretory protein. Only after removal of the SP did the NLS-fused DNase1 relocate to the nucleus. The nucleus was strongly stained for DNase1-GFP and the cytoplasm was almost completely depleted of staining regardless of whether the NLS was positioned at the N-terminus or C-terminus. Modified DNase1 triggers apoptosis in melanoma K Rosner et al Melanoma cell survival decreased most prominently after treatment with the NLS-fused and actin-resistant DNase1 gene constructs C11 and C13 Colony forming assay. Neither WT DNase1 nor C09 or C07 constructs decreased cell survival significantly compared with the Cat-GFP control (PX0.12). This suggests that overexpression of WT DNase1 is not sufficient to induce cytotoxicity. The results also suggest that removing the SP from DNase1 to prevent it from being compartmentalized within the secretory organelles, and equipping it with an NLS to gain access to the nucleus, are not sufficient to confer cytotoxicity to DNase1 protein. In contrast, C11 and C13 constructs decreased cell survival to 23.2 and 32.4%, respectively, compared with Cat-GFP control (Po0.0001). Also, C11 and C13 decreased cell survival significantly compared with WT DNase1, C07 or C09 constructs (P ¼ 0.0003).
C11 and C13 did not significantly differ in their potency to reduce cell survival (P ¼ 0.81). Taken together with the lack of cytotoxicity displayed by C07 and C09, these results suggest that the nuclear-targeted DNase1 is inactivated by actin. Therefore, rendering actin-resistance to the nuclear-targeted DNase1 is crucial for inducing cytotoxicity. To address the question of whether C11 and C13 induced cytotoxicity directly by their catalytic activity, the H252A substitution was introduced into the catalytic site of DNase1, generating C18 and C19, respectively. The substitution increased melanoma cell survival from 23.2 (C11) to 61.7% (C18; P ¼ 0.0003) and from 32.4 (C13) to 100% (C19; P ¼ 0.0008; Figure 5 ), suggesting that the DNase1 constructs directly impact cytotoxicity.
Apoptosis of melanoma cells was most significant after treatment with the NLS-fused and actin-resistant DNase1 gene constructs C11 and C13 Morphological assessment and TUNEL assay for apoptosis analysis. Representative examples of characteristic apoptotic morphology and DNA nicking, analyzed with phase contrast microscopy and TUNEL assay, are presented in Figure 6 . After treatment with DNase1 gene constructs, a substantial number of TUNEL-positive cells and cells displaying apoptotic characteristics were evident. These characteristics, including cytoplasm and nuclear condensation and cell membrane blebbing, were minimal after 12 h and pronounced after 24 h. The characteristics were observed only after treatment with actin-resistant DNase1 gene constructs, C11 and C13, and only sporadically with other constructs or controls, because of background apoptosis ( Figure 6 ). Background apoptosis can reflect spontaneous apoptosis that occurs in untreated neoplasms or apoptosis induced by DNA-liposome complexes. 32, 33 DNA fragmentation assay for apoptosis assessment. DNA fragmentation was most extensive after treating melanoma cells with the actin-resistant DNase1 gene constructs (C11 and C13), reduced after treatment with either C19 or C07, and minute or absent after treatment with C18, C07 or WT DNase1 (Figure 7 ). These observations were minimal after 12 h and pronounced after 24 h. However, the partial degradation of DNA observed for C19 and C07 constructs was not reflected with TUNEL, LSC and colony forming assays and, therefore, may reflect variations in experimental conditions. DNA fragmentation in the form of a smear is characteristic of DNase1. 28, 34 For the induction of the classical DNA laddering form of DNA degradation (low molecular weight DNA fragmentation), DNase1 requires the removal of DNA binding proteins, which are released during cell damage conditions such as necrosis. 28, 34 Apoptotic melanoma cell quantification by LSC for apoptosis assessment. LSC quantifies cell populations on the basis of their immunofluorescence emission. The calculated mean and range of positive cells for Cat-GFP, C11, C13 and WT DNase1-treated populations were 14.2% (9.9-18.6%), 11% (7.3-20.2%), 5.4% (4.0-7.8%) and 1.8% (0.1-2.9%), respectively. Killing efficiency reflects the ratio between cells undergoing apoptosis and positively transfected cells; thus, the killing efficiency values for C11 and C13 were 70-100% and 40%, respectively. Compared with mock-treated cells, the number of positive cells was significantly higher for actin-resistant DNase1 gene constructs (C11 and C13; P ¼ 0.004 and P ¼ 0.03, respectively), but not for WT DNase1 (P ¼ 0.92; Figure 8 Modified DNase1 triggers apoptosis in melanoma K Rosner et al
Discussion
In this study, we pursue an approach of triggering apoptosis in cancer cells without activating the apoptotic-signaling cascade. We chose to bypass the signaling cascade as well as possible inhibitors of nuclear endonucleases by constructing a genetically modified wastemanagement enzyme, DNase1.
We used the Mel-Juso human melanoma cell line because of its known high resistance to apoptosis. This feature results from multiple molecular changes such as mutations in the pro-apoptotic RAS gene or overexpression of the strong anti-apoptotic Bcl-xL, a member of the Bcl-2 family. [35] [36] [37] The Mel-Juso cell line is chemoresistant 35 and displays higher resistance to UVB-induced apoptosis than other melanoma cell lines. 38 Also, it is not sensitive to Fas or TRAIL-induced apoptosis. 39 As a result, this cell line is most suitable for testing new pro-apoptotic therapies.
Overexpression of wild-type DNase1 was not sufficient to induce apoptosis We demonstrated that overexpression of a full length DNase1 complementary DNA with an N-terminal SP did not decrease melanoma cell survival ( Figure 5 ). Our observations are in contrast to the report, which claimed that overexpression of WT DNase1 alone was sufficient to trigger apoptosis in COS-cells. 40 In that study, DNA from nuclei that were isolated from transfected cells, showed multiple 200 bp fragments. 40 The authors suggested that overexpressed WT DNase1 could enter the nucleus and trigger apoptosis. However, there is an alternative explanation, namely, contamination of the nuclear extract with DNase1 from intracellular storage. This possibility is supported by the study's finding of classic intranucleosomal-DNA fragmentation of 200 bp fragments. This fragmentation pattern, however, is not typically generated by DNase1 nucleolysis unless it is associated with proteolysis by proteins released from lysosomes. 28, 34 Moreover, in a similar study of COS-cells, the same group claimed that the overexpressed WT DNase1 gained access to the nucleus after both the nuclear envelope and the endoplasmic reticulum broke down. 41 Hence, the overexpressed WT DNase1 did not trigger apoptosis, but joined the process as a late player. By contrast, our findings are supported by studies showing that an overexpressed DNase1 with an N-terminal SP does not localize to the nuclei of NIH-3T3 cells nor does it produce DNA fragmentation in C2C12 cells. 28 Removing the SP and adding a NLS are not sufficient to lend DNase1 the ability to induce apoptosis We found that NLS failed to target DNase1 to the nucleus in the presence of SP (Figure 4) . Therefore, it is conceivable that eliminating SP and adding NLS would provide DNase1 access to the nucleus and the opportunity to defragment the genomic DNA. To test this notion, we generated the C07 and C09 DNase1 constructs that had NLS fused to DNase1's N-terminus and C-terminus, respectively. However, we found that overexpression of modified DNase1 complementary DNA (C07 and C09) did not decrease melanoma cell survival ( Figure 5 ). Our results suggest that replacing SP with an NLS is not sufficient to enable DNase1 to trigger apoptosis significantly. As C07 and C09 did not differ in their impact on cell viability, failure of the modified DNase1 to induce apoptosis cannot be attributed to the N-terminal or C-terminal NLS fusion. Removal of SP from the DNase1 protein may alter glycosylation at amino acid site 18 and 106. 30 However, glycosylation is not required for DNase1 activity. 42, 43 SP elimination was reported to result in the cytoplasmic distribution and nuclear accumulation of WT DNase1 fused to GFP. 28 However, in that report, the authors acknowledged that the GFP degradation product, which was present in all transfections, could have compromised the immunofluorescence localization studies. 28 Overexpression of a DNase1 gene construct with three modifications: a mutated actin-binding site, deleted SP and added NLS, successfully triggered apoptosis in human melanoma cells We tested the possibility that nuclear actin inhibited the activity of NLS-fused DNase1 constructs, C07 and C09.
To that aim, we mutated the binding site of DNase1 (A114F) in C07 and C09, to create actin-resistant DNase1 constructs, C13 and C11, respectively. These constructs included three genetic alterations: (i) eliminated SP, (ii) fused NLS and (iii) mutated actin-binding site. A114F substitution has previously been reported to increase the potency of WT DNase1 by approximately fivefold. 44 These alterations provided C11 and C13 constructs with access to the nucleus and resistance to actin inhibition. We found that C11 and C13 constructs induced apoptosis (Figures 6-8 ) and decreased melanoma cell survival ( Figure 5 ) significantly more than WT DNase1 did. It is conceivable that C11 and C13 constructs induced DNA damage, which in turn triggered apoptosis. 45, 46 Also, our findings showed that C11 induced apoptosis more effectively than C13. This could be explained by lower C13 synthesis (Figure 3b) or alternatively, by a steric effect of the fused NLS to the N-terminus that could compromise the activity site. Our findings reaffirm actin's protective role in human cells against DNase1 and against premature cell death. 16 We do not exclude the possibility of inducing apoptosis with a non-actin-resistant DNase1 targeted to the nucleus. This may occur in cell types expressing low nuclear G-actin levels. However, conferring actin resistance to DNase1 offers a significant advantage, as we showed in our human melanoma cells.
Next, we investigated whether DNase1 constructs triggered apoptosis directly using their catalytic activity, or indirectly through mediators. We mutated one of two catalytic sites of DNase1, H252A, in C11 and C13, , WT DNase1 and C18 were 11.1%, 5.4%, 1.8% and 0.9%, respectively, and for all other samplesp0.3%. *P ¼ 0.004 with respect to mock; **P ¼ 0.02 with respect to WT DNase1 (n ¼ 3). Untr., untreated cells; WT, wild-type DNase1.
generating DNase1 constructs C18 and C19, respectively. This substitution has been reported to decrease WT DNase1 activity by B10-fold. 47 We found that knocking down the activity site resulted in restoration of cell survival ( Figure 5 ), as well as reduction in the number of apoptotic cells (Figure 8 ) and chromatin-degrading effect (Figure 7 ). These findings suggest that C11 and C13 triggered apoptosis by direct cleavage of the genomic DNA through their catalytic site.
Killing efficiency of actin-resistant DNase1 constructs fused with NLS and lacking SP The population of cells undergoing apoptosis (TUNEL positive) was not larger than the transfected cell population (Cat-GFP positive; p1) for any of the DNase1 constructs. This may suggest a lack of the 'bystander effect' characteristic of herpes simplex virus thymidine kinase, the most investigated mode of suicide gene therapy. Herpes simplex virus thymidine kinase relies heavily on the 'bystander effect,' which refers to killing neighboring non-transduced cancer cells in addition to killing Ganciclovir-treated herpes simplex virus thymidine kinase-transduced cells. However, the 'bystander effect' is also associated with the side-effect of killing normal cells such as human ovarian epithelial cells and lens epithelial cells. 48, 49 Herpes simplex virus thymidine kinase treatment for hepatocellular carcinoma was associated with death of 9 out of 19 rats. 50 Therefore, the finding that DNase1 constructs did not show the 'bystander effect' suggests an important safety advantage, adding to its high killing efficiency in treating resistant cancers such as melanoma. This finding should be further confirmed in additional studies.
Low transfection rates by conventional transfection procedures, as shown in our LSC assay, have had limited gene-therapy efficiency over the last two decades. Recently, transfection rates have increased to a level greater than 95% with a new generation of vectors such as lentiviruses. 49 This can have a synergistic role in the clinical implementation of DNase1 gene constructs.
In summary
We have shown that the waste-management enzyme DNase1 can be genetically modified to bypass cancer's anti-apoptotic defense mechanisms and to trigger apoptosis in human melanoma cells without a pharmacological adjuvant. Further experiments using animal models will be performed to determine the anti-cancer efficiency of the DNase1 gene constructs in vivo.
